Botulinum toxin A in the treatment of blepharospasm: a 10-year experience

To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.

Saved in:
Bibliographic Details
Main Authors: Silveira-Moriyama,Laura, Gonçalves,Lilian R., Chien,Hsin Fen, Barbosa,Egberto R.
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2005
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200006
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2005000200006
record_format ojs
spelling oai:scielo:S0004-282X20050002000062005-07-05Botulinum toxin A in the treatment of blepharospasm: a 10-year experienceSilveira-Moriyama,LauraGonçalves,Lilian R.Chien,Hsin FenBarbosa,Egberto R. botulinum toxin blepharospasm dystonia To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.63 n.2a 20052005-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200006en10.1590/S0004-282X2005000200006
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Silveira-Moriyama,Laura
Gonçalves,Lilian R.
Chien,Hsin Fen
Barbosa,Egberto R.
spellingShingle Silveira-Moriyama,Laura
Gonçalves,Lilian R.
Chien,Hsin Fen
Barbosa,Egberto R.
Botulinum toxin A in the treatment of blepharospasm: a 10-year experience
author_facet Silveira-Moriyama,Laura
Gonçalves,Lilian R.
Chien,Hsin Fen
Barbosa,Egberto R.
author_sort Silveira-Moriyama,Laura
title Botulinum toxin A in the treatment of blepharospasm: a 10-year experience
title_short Botulinum toxin A in the treatment of blepharospasm: a 10-year experience
title_full Botulinum toxin A in the treatment of blepharospasm: a 10-year experience
title_fullStr Botulinum toxin A in the treatment of blepharospasm: a 10-year experience
title_full_unstemmed Botulinum toxin A in the treatment of blepharospasm: a 10-year experience
title_sort botulinum toxin a in the treatment of blepharospasm: a 10-year experience
description To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000200006
work_keys_str_mv AT silveiramoriyamalaura botulinumtoxinainthetreatmentofblepharospasma10yearexperience
AT goncalveslilianr botulinumtoxinainthetreatmentofblepharospasma10yearexperience
AT chienhsinfen botulinumtoxinainthetreatmentofblepharospasma10yearexperience
AT barbosaegbertor botulinumtoxinainthetreatmentofblepharospasma10yearexperience
_version_ 1756374297389039616